Her2

Her2 - most related articles:

- SPOT-Light HER2 CISH kit approved for breast cancer patients - 5.8
- Inform Dual ISH to determine HER2 gene in breast cancer patients - 5.6
- HER growth proteins do not predict outcome of herceptin treatment breast cancer patients - 4.8
- Herceptin with chemotherapy improves breast cancer survival - 4
- Neratinib shows promise in trastuzumab resistant breast cancer - 3.7
- Breast cancer gene responds to blood pressure drug in lab - 3.6
- Novartis drug Afinitor everolimus helps advanced breast cancer women - 3.5
- FDA panel votes to revoke approval for Avastin for advanced breast cancer - 3.3
- Avastin found effective in advanced breast cancer patients - 3
- Triple drug combination promising to treat breast cancer - 3

Her2 articles

HER growth proteins do not predict outcome of herceptin treatment breast cancer patients
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2 Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

FDA panel votes to revoke approval for Avastin for advanced breast cancer
The Oncologic Drugs Advisory Committee, FDA, USA disapproved the Avastin which cited a lack of survival benefit. Now as two more trials have been analyzed -- neither showing a survival benefit -- the FDA stated that in the balance, the benefit did not outweigh the harm.

Inform Dual ISH to determine HER2 gene in breast cancer patients
Breast cancer is the second leading cause of cancer-related death among women. About 20 percent of women diagnosed with breast cancer are HER2-positive. The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. Patients with more than the normal number of copies of the HER2 gene are considered candidates for Herceptin therapy.

Herceptin with chemotherapy improves breast cancer survival
Using Herceptin with chemotherapy clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher.

Math may predict Herceptin response in breast cancer patients
Cancer researchers are turning to mathematical models to help answer important clinical questions, and a new paper in Cancer Research, a journal of the American Association for Cancer Research, illustrates how the technique may answer questions about Herceptin resistance.

Neratinib shows promise in trastuzumab resistant breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies.

Triple drug combination promising to treat breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

SPOT-Light HER2 CISH kit approved for breast cancer patients
SPOT-Light HER2 CISH kit - a novel genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin (trastuzumab) has been approved by the U.S. Food and Drug Administration.

Genentech's Avastin with chemotherapy approved for advanced breast cancer
Genentech, Inc. (NYSE: DNA) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Avastin (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.

Avastin found effective in advanced breast cancer patients
Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin® (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.

Breast cancer sufferers demand answers from PHARMAC, New Zealand
8 cancer survivors are in the New Zealand High Court to fight their case against drug funding agency PHARMAC. The women are challenging PHARMAC's decision not to fund 12 months of Herceptin treatment for NZ women with HER2 positive breast cancer.

11 Her2 articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.05